This study is a randomized controlled trial comparing the effects of socket grafting with crushed vitamin K2 (menaquinone)capsules versus no grafting on bone density and socket dimensions following tooth extraction. Patients are randomly assigned to one of two groups:
Study Group (Group I): Patients receive socket grafting with crushed vitamin K2 (menaquinone) capsules. The socket is covered with an absorbent sponge, and non-resorbable sutures are placed to stabilize the graft material and achieve soft tissue stability.
Control Group (Group II): Patients undergo socket healing without grafting. The socket is covered with an absorbent sponge, and non-resorbable sutures are placed over it.
Outcome measures include bone socket dimensions evaluated immediately after extraction with graft material, as well as assessment after 4 months using cone beam computed tomography (CBCT) radiographs. Additionally, core biopsies are taken at the time of implant placement.

Start Date15 Feb 2025

Sponsor / Collaborator

Cairo University

DRKS00034742

/ RecruitingNot ApplicableIIT

Vitamin supplementation in cystic fibrosis in the era of modulators: the impact of vitamin K2 on cardio-metabolic health – a randomised double-blind placebo-controlled trial

Start Date29 Oct 2024

Sponsor / Collaborator-

ChiCTR2400081931

/ SuspendedNot ApplicableIIT

The effect of vitamin K2 fortified nutritional intervention on muscle condition and clinical outcomes in elderly patients with muscle wasting syndrome

Start Date19 Mar 2024

Sponsor / Collaborator-

100 Clinical Results associated with Menatetrenone

100 Translational Medicine associated with Menatetrenone

100 Patents (Medical) associated with Menatetrenone

1,948

Literatures (Medical) associated with Menatetrenone

01 Mar 2025·Nutrition

Vitamin K2 deficiency and its association with short stature in children: A cross-sectional study

Article

Author: Tang, Ai-Jie ; Li, Zhe ; Cao, Rui-Xue ; Liu, Pei-Ning ; Zhou, Fan ; Xu, Ke-Wen ; Liu, Jin-Rong ; Chen, Li-Li ; Shen, Guang-Hui

OBJECTIVESThis study examines the relationship between vitamin K2 (VK2) status and the occurrence of short stature in children.METHODSA cross-sectional analysis was conducted between January 2021 and August 2022, involving 235 children with a clinical diagnosis of short stature at the Second Affiliated Hospital of Wenzhou Medical University (short stature group) and 454 children with average height (±1 SD) from the same period (healthy group). Serum VK2 levels were compared between the two groups. Multivariate logistic regression analysis was used to identify factors associated with short stature, and spearman correlation analysis was used to examine the relationship between VK2 status and age.RESULTSChildren in the short stature group exhibited lower VK2 levels (P = 0.019) and a significantly higher prevalence of VK2 deficiency (P = 0.011) compared to the healthy group. VK2 deficiency was identified as an independent risk factor for short stature (OR = 1.535, 95% CI = 1.061-2.222, P = 0.023) through multivariate logistic regression analysis. Furthermore, an inverse correlation was observed between serum VK2 levels and age in children aged 2 to 15 years (ρ = -0.133, P < 0.001).CONCLUSIONSVK2 deficiency may be associated with an increased risk of short stature in children.

01 Mar 2025·European Journal of Pharmacology

Vitamin K2 protects against D-galactose induced ageing in mice

Article

Author: Mazumder, Papiya Mitra ; Chatterjee, Kaberi ; Banerjee, Sugato

BACKGROUNDAgeing is a complex process characterized by the gradual deterioration of physiological functions, often leading to a diminished quality of life. Dementia is among the prominent indicators of ageing characterized by cognitive impairment. Animal studies employing D-galactose have provided insights into the mechanisms underlying cognitive decline and neuronal degeneration, resembling features of human brain ageing while Vitamin K2, known for its diverse physiological functions, also have neuroprotective potential. Here we study the effect of Vitamin K2 in D-galactose induced ageing in mice.METHODSAgeing was induced in adult Swiss albino mice using D-galactose via subcutaneous (SC) route for 45 days while one group of animals received Vitamin K2 (MK-7) via oral gavage during last 21 days. Then different behavioral studies, including the elevated plus maze, Morris water maze, passive avoidance and novel object recognition test were performed to measure cognitive changes, followed by measuring AChE, corticosterone (plasma), oxidative stress parameters (SOD, GSH, MDA) and pro-inflammatory markers (TNFα, IL1β) in hippocampal homogenates. Histopathology of the hippocampal sections were performed to measure neuronal density.RESULTSVitamin K2, treatment reversed D-galactose associated memory changes. In the biochemical studies, plasma corticosterone was reduced while hippocampal AChE, MDA and pro-inflammatory cytokines were reduced after Vitamin K2 treatment. The antioxidants like SOD and GSH were improved in Vitamin K2 treated animal brain. The hippocampal neuronal density increased in treatment group compared to D-galactose induced aged animals.CONCLUSIONTreatment with Vitamin K2 (MK-7) partially reversed cognitive decline associated with ageing, highlighting its potential as a therapeutic intervention for age associated cognitive decline.

01 Mar 2025·Clinical Rheumatology

Ectopic calcifications in the musculoskeletal field: the basis for preventive and curative pharmacological strategies

Review

Author: Milovanovic, Petar ; Popovic, Ana ; Savic, Ivana ; Grajic, Mirko

Ectopic calcifications occur in tendons, ligaments, entheses, muscles, and fasciae, and are often associated with pain and inflammation. In clinical settings, these calcifications are commonly treated by physical therapy and/or surgical interventions. However, there is not enough understanding of pharmacological treatments as primary cures, supportive therapy to physical or surgical treatment, or even preventive measures to avoid or diminish the development of ectopic calcifications. Here, we summarize preclinical and clinical evidence for pharmacological candidates for treatment/prevention of ectopic calcification in the context of painful syndromes in the musculoskeletal field. Specifically, we discuss the potential mechanisms of nonsteroidal anti-inflammatory drugs, corticosteroids, H2-receptor blockers, bisphosphonates, minocycline, biologics, ACTH analogues, colchicine, calcium channel blockers, vitamins K2 and D, magnesium, zinc, curcumin, and phytates. Given that ectopic calcification is sometimes paradoxically associated with reduced bone mineralization, it appears particularly reasonable to employ strategies that can both inhibit ectopic calcification and promote bone mineralization, such as bisphosphonates and the combination of vitamin K2 and vitamin D, along with other supplements such as magnesium and zinc. Future studies need to test whether differential therapeutic approaches are needed in different phases of the disease and whether different mechanisms of ectopic calcification require different therapeutic strategies. A precondition for such approaches is further clinical and/or imaging delineation and differentiation of various types and phases of calcific diseases. Finally, it is essential to ensure that anti-calcification effects of new treatment strategies do not harm bone formation and skeletal mineralization.

News (Medical) associated with Menatetrenone

04 Jan 2024

·www.globenewswire.com

Healthy Extracts Launches First Anti-Aging Formulation, LONGEVITY

LAS VEGAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, has launched LONGEVITY Anti-Aging™, a new proprietary formulation designed to support skin vitality, arterial flexibility, and cellular and joint health. LONGEVITY Anti-Aging is available to order today on BergametNA.com. In celebration of the launch, for a limited time you can buy two and get one free. You can also subscribe and save 15% on every order. The formulation is a special blend of the most powerful anti-aging warriors that include trans-resveratrol, quercetin, vitamin D, and vitamin K2. These substances are known to boost blood flow and circulation, reduce the deleterious effects of misplaced calcium in the body, and slow the effects of aging with powerful antioxidants. “LONGEVITY Anti-Aging complements our growing heart health product portfolio which supports a holistic approach to anti-aging like healthy skin,” noted Healthy Extracts president, Duke Pitts. “We anticipate this new product, along with the others we’re planning to launch early this year, will continue drive our growth and market expansion, as they leverage our multiple sales and distribution channels and existing customer base.” LONGEVITY Anti-Aging represents a holistic approach to aging, with a proprietary blend focused on providing the nutrition the body needs for optimal health. It is formulated to help sustain vitality, support heart health, ensure robust bone strength, and contribute to a healthier aging process. The formulation is vegan friendly, non-GMO, gluten-free, and produced and tested by certified U.S. facilities. Key substances and benefits: Trans-resveratrol and quercetin are powerful antioxidants that shield cells from aging and oxidative stress for more youthful function.Vitamin D and K2 are vital for proper calcium absorption and distribution, bolstering bone health and reducing osteoporosis risk.For heart health, ingredients like vitamin K2 and trans-resveratrol are key in maintaining cardiovascular wellness, helping to lower the risk of heart ailments.Vitamin D and quercetin also strengthens immune defense, enhancing protection against infection and disease. LONGEVITY Anti-Aging is your ally for overall longevity, blending ingredients renowned for their anti-aging benefits that support a longer, healthier life. LONGEVITY Anti-Aging introduction follows the recent official launch of BERGAMET SLEEP BREATHING SUPPORT™ , a natural supplement designed to support respiratory function for deeper, more restorative sleep. Given the better than anticipated initial sales of this new product, it is on track to become one of the company’s best sellers in 2024. Healthy Extracts’ full line of natural heart health formulations address the fast-growing, multi-billion dollar heart-health supplement market which is projected to grow at 5.9% CAGR to reach $24.8 billion by 2027, according to ResearchAndMarkets. To learn more about Healthy Extracts’ full line of clinically-backed, natural brain and hearth health products, go to bergametna.com or tryubn.com. About Healthy Extracts “Live Life Young Again” Healthy Extracts Inc. is a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals. The company’s subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™. This superfruit has the highest known concentration of polyphenols and flavonoids. UBN’s KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities. For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on March 31, 2023, and future periodic reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release. Food & Drug Administration Disclosure The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor’s advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™ Company ContactDuke Pitts, PresidentHealthy Extracts Inc.Tel (720) 463-1004Email contact Investor ContactRonald Both CMA Investor RelationsTel (949) 432-7566Email contactMedia Contact:Tim RandallCMA Media RelationsTel (949) 432-7572Email Contact A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/200b922a-c04a-45ab-b819-dba1b9750c42

Drug Approval

07 Mar 2023

·www.prnewswire.com

NUTRISHOP® Launches Comprehensive Heart Formula To Support Cardiovascular Health

Heart Formula by Nu-Tek Nutrition® is now available exclusively at Nutrishop HENDERSON, Nev., March 7, 2023 /PRNewswire/ -- Nutrishop, a leading national retail nutrition franchise specializing in dietary and nutritional supplements, vitamins and wellness, is proud to announce the launch of Heart Formula by Nu-Tek Nutrition®. This product's comprehensive approach to cardiovascular health contains some of the most sought-after, heart-healthy ingredients on the market. And, it is now available exclusively through Nutrishop. Continue Reading "We all have only one heart, and it is never too early to start caring for it." Tweet this Let’s face it, wellness is the new fitness. Introducing Heart Formula by Nu-Tek Nutrition. It’s loaded with heart-healthy ingredients like Olive Leaf Extract, Garlic, Organic Beet Root, Turmeric, CoEnzymeQ10, and more. Let’s be as healthy on the inside as we look on the outside. "We all know the importance of a healthy heart, yet some of us may overlook it in pursuit of a fit physique. However, the importance of a healthy heart cannot be overstated," said Nutrishop Founder and CEO Bryon McLendon. "If the interior of our bodies is not functioning properly, nothing on the exterior matters. Nu-Tek Nutrition's Heart Formula is the perfect solution to support our body's most important muscle." Loaded with heart-healthy ingredients such as Olive Leaf Extract, Garlic Extract, Turmeric Root, Hawthorn Berry, Organic Beet Root, CoEnzymeQ10, Grape Seed Extract, and Vitamin K2, Heart Formula is easy to incorporate into any wellness routine. In addition to maintaining a healthy body weight, regularly engaging in cardio exercise (brisk walking counts!), reducing stress and consuming good-for-your-heart foods, such as salmon, vegetables, whole grains, nuts and seeds, simply take three capsules daily or as directed by your healthcare professional. "We all have only one heart, and it is never too early to start caring for it," McLendon said. "With Heart Formula by Nu-Tek Nutrition combined with a healthy lifestyle, you're definitely stepping in the right direction." To learn more or purchase Heart Formula, visit NutrishopUSA.com or stop by any Nutrishop location nationwide. About Nu-Tek Nutrition ®: For nearly 20 years, Nu-Tek Nutrition has dedicated itself to building the foundation of health and wellness with innovative, complex powders like Supergreens, Superfruits, and Daily Detox and supplements like Gut Formula and Super Multi+. The brand's products are backed by over 25 years of formulating experience to offer the best wellness supplementation and help people live their best lives. About NUTRISHOP ® Since 2003, NUTRISHOP® has helped countless individuals live a fit, healthy, happy lifestyle. Nutrishop stores offer customers a low-price guarantee on a wide array of cutting-edge dietary supplements along with exceptional, individualized customer service, easy-to-follow meal plans, body composition assessment tools, and sound nutritional guidance. The Nutrishop business model focuses primarily on franchisee-owned and operated stores that provide consumers with the tools required to achieve their health and fitness goals. For more information, visit NutrishopUSA.com and follow on Instagram @NutrishopUSA. To learn more about becoming a Nutrishop franchisee, visit NutrishopFranchise.com. SOURCE Nutrishop

03 Aug 2022

·www.worldpharmanews.com

Vitamin K prevents cell death: a new function for a long-known molecule

Vitamin K is well-known for its blood clotting and bone building properties but today a new study published in Nature reports on a novel function for vitamin K. The researchers discovered that the fully reduced form of vitamin K acts as an antioxidant efficiently inhibiting ferroptotic cell death. Ferroptosis is a natural form of cell death in which cellular iron plays an important role and which is characterized by the oxidative destruction of cellular membranes. In addition, the team identified FSP1 as the warfarin-insensitive enzyme reducing vitamin K, the identity of which had been postulated but remained unknown for more than half a century. During the last years, ferroptosis has been implicated as a driver of Alzheimers disease and acute organ injuries among many other diseases. Thus, the present findings put forward the concept that vitamin K treatment might be a new powerful strategy to ameliorate these ferroptosis-related diseases. Vitamin K is a potent ferroptosis suppressor Since ferroptosis prevention is considered a highly promising approach for the therapy of many degenerative diseases, new mechanisms and compounds regulating ferroptosis are extensively being explored. To identify these new molecules, a team of researchers led by Dr. Eikan Mishima and Dr. Marcus Conrad, both from the Institute of Metabolism and Cell Death at Helmholtz Munich, along with collaborators from Tohoku University (Japan), University of Ottawa (Canada) and Technical University of Dresden (Germany), systematically studied a number of naturally occurring vitamins, as well as their derivatives. "Surprisingly, we identified that vitamin K, including phylloquinone (vitamin K1) and menaquinone-4 (vitamin K2), is able to efficiently rescue cells and tissues from undergoing ferroptosis" Dr. Eikan Mishima, first author of the study explained. Unraveling the long sought-after vitamin K reducing enzyme FSP1 In 2019 a team of researchers around Dr. Marcus Conrad already identified an enzyme as a novel and strong inhibitor of ferroptosis: ferroptosis suppressor protein-1, short FSP1. At the time, the team showed that FSP1 reduced coenzyme Q10 to its hydroquinone, which suppressed ferroptosis. The research team now found that the fully reduced form of vitamin K (i.e., vitamin K hydroquinone) is, like the reduced form of coenzyme Q10, a strong lipophilic antioxidant and prevents ferroptosis by trapping oxygen radicals in lipid bilayers. "The reduced forms of Vitamin K and coenzyme Q10 are not very stable, so our finding that FSP1 can maintain them in their active (reduced) state is key to understanding how they are able to function to maintain cell viability." explained Derek A. Pratt, co-author and University Research Chair in Free Radical Chemistry at the University of Ottawa. In addition, they identified that FSP1 is the enzyme that efficiently reduces vitamin K to vitamin K hydroquinone, thereby driving a novel non-canonical vitamin K cycle. Since vitamin K is critically involved in blood clotting processes, the team further showed that FSP1 is responsible for the vitamin K-reduction pathway insensitive against warfarin, one of the most commonly prescribed anticoagulants. Breakthrough in understanding vitamin K metabolism Unraveling the identity of this enzyme solved the last riddle of vitamin K metabolism in blood clotting and elucidated the molecular mechanism of why vitamin K constitutes the antidote for overdosing of warfarin. "Our results therefore link the two worlds of ferroptosis research and vitamin K biology. They will serve as the stepping stone for the development of novel therapeutic strategies for diseases where ferroptosis has been implicated," Dr. Marcus Conrad highlighted. In addition, since ferroptosis most likely constitutes one of the oldest types of cell death, the researchers hypothesize that vitamin K might be one of the most ancient types of naturally occurring antioxidants. "Thus, new aspects of the role of vitamin K throughout the evolution of life are expected to be unveiled," Dr. Marcus Conrad explained. Mishima E, Ito J, Wu Z et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Nature, 2022. 10.1038/s41586-022-05022-3

100 Deals associated with Menatetrenone

External Link

KEGG	Wiki	ATC	Drug Bank
D00100	Menatetrenone	B02BA	DB12148

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Osteoporosis, Postmenopausal	China	Eisai Co., Ltd.	21 Jul 2013
Vitamin K Deficiency Bleeding	Japan	Sannova KK	25 May 2012
Vitamin K Deficiency Bleeding	Japan	Alfresa Pharma Corp.	25 May 2012
Pain	China	Eisai Co., Ltd.	29 Jun 2010
Osteoporosis	Japan	Eisai Co., Ltd.	30 Jun 1995
Hemorrhage	Japan	Eisai Co., Ltd.	29 Jun 1972
Hypoprothrombinemias	Japan	Eisai Co., Ltd.	29 Jun 1972

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatocellular Carcinoma	Phase 2	Japan	Eisai Co., Ltd.	01 Mar 2004
Cerebral Hemorrhage	Preclinical	Japan	Kumamoto University	10 May 2024
Leukemia	Preclinical	Japan	Tokyo Medical University	16 Nov 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MO789 (ERA2022)	Not Applicable	matrix Gla protein (MGP)	120	Vitamin K1	etocrazpwt(xgtfneamik) = vmhqdeqgon xgrjbwtgjg (qhmiexclzz )	Positive	03 May 2022
				Vitamin K2	etocrazpwt(xgtfneamik) = fyehndqbai xgrjbwtgjg (qhmiexclzz )
WCO_IOF_ESCEO2022	Not Applicable	Osteoporosis, Postmenopausal	46	Vitamin K2 (Women with Postmenopausal Osteoporosis)	gnrwxxbviy(vpzgsinwkz) = ztvgaiodow jkyrjlmppf (lzgonijilc, 10.09) View more	-	24 Mar 2022
				Vitamin K2 (Postmenopausal Women without Osteoporosis)	gnrwxxbviy(vpzgsinwkz) = irjiuprhri jkyrjlmppf (lzgonijilc, 6.94) View more
FP608 (ERA2019)	Not Applicable	Vascular Calcification uncarboxylated-MGP	102	Vitamin K2 supplementation (200μg/day)	yuzrtaxxeo(cvjucrntmh) = daghagwebn tcercwrqqc (bjfeisnpay ) View more	Negative	13 Jun 2019
				Vitamin K2 (Control (no treatment))	yuzrtaxxeo(cvjucrntmh) = iuwvedgvsg tcercwrqqc (bjfeisnpay ) View more
NCT01101698 \| NCT04247087 (Pubmed \| Pol Arch Intern Med)	Phase 4	Chronic Kidney Diseases	42	Vitamin K2 + cholecalciferol (K+D)	epxcgqhagp(nkaaedwrxr) = pocdnbjncz cbwolmclna (vcsjkiqntz )	-	01 Jan 2015
				Cholecalciferol (D)	epxcgqhagp(nkaaedwrxr) = xzjgmltnbm cbwolmclna (vcsjkiqntz )
ASN2013	Not Applicable	Chronic glomerulonephritis \| Glucocorticoid-induced osteoporosis N-terminal telopeptide of type I collagen (NTx) \| uncarboxylated osteocalcin (ucOC)	43	Etidronate	jtxxlzewej(erzvmvprqq) = There were no significant differences in BMD between these groups during the study upvrkimlcz (eofsgzapsf )	Positive	05 Nov 2013
				Etidronate+Menatetrenone
ASN2012	Not Applicable	dp-uc-MGP	200	Vitamin K2 360 µg	noaqkjkhcr(tzgsrntoxl) = 13% of patients suffered from gastro-intestinal side effects, unrelated to the dose. Nausea caused by the unpleasant smell of the uncoated tablets was reported most frequent. rqstoptjuw (trdenrufqe )	Positive	30 Oct 2012
				Vitamin K2 720 µg
NCT00165698 (CTgov)	Phase 3	Osteoporosis, Postmenopausal	240	Menatetrenone (Menatetrenone)	rbaezykyds(oljtejohah) = rwalbnpyio andecaumnc (aeaipspxgm, avyedskghz - gaunfeghzw) View more	-	11 Aug 2011
				Alfacalcidol (Alfacalcidol)	rbaezykyds(oljtejohah) = xmnmehnrwr andecaumnc (aeaipspxgm, zyrhahtyzr - zyxopsxjts) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Menatetrenone

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation